📢 New publication in Nature Medicine! The phase 2 #ATRACTIB trial tested atezolizumab + paclitaxel + bevacizumab as 1L for advanced TNBC, regardless of PD-L1 status. 🕒 Median PFS: 11 months 🎯 ORR: 63% 🔗 Read the full article here 👉🏼 www.nature.com/articles/s41... #BreastCancer

We leave #ASCO25 with full hearts and minds brimming with science. Presenting #TUXEDO3, sharing #ADELA & #WINB, and connecting with passionate people—this is what drives us. Thank you all. We take home more than results. Time to rest… until next time!

#MEDSIRatASCO Dr. Tim Robinson breaks down the #WINBtrial, a study aiming to boost the effectiveness of sacituzumab/govitecan in breast cancer (TNBC & HR+). Despite its promise, many patients don't respond or progress quickly.

Dr. María Gion presented #WINBtrial results, a phase Ib/II trial in pretreated HR+/HER2- & TNBC. 📌Sacituzumab govitecan + Debio 0123, a selective, brain-penetrant WEE1 inhibitor. 💡Phase Ib sets dose for phase II, aiming tumor regression.

#MEDSIRatASCO Day 4! Isabel Tundidor shares how we combine hard work, science & collaboration during these intense (but rewarding) days. 👉🏼 www.youtube.com/shorts/Qxsac... #ASCO25 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#GoodMorning MEDSIR Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5). 📍 WINB: #479b 📍 ADELA: #103b 👉🏼 medsir.org/events/asco2... #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀 👉🏼 www.youtube.com/shorts/jcVK6... #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options. 🎥 Watch Dr. Preusser explain more 👇 www.youtube.com/watch?v=bjyy...

#GoodMorning MEDSIR! Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀 👉🏼 Stay tuned: lnkd.in/dkDs-bp4 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO Have you seen our exclusive newsletter from #ASCO25? 👉 Special Guest: Dr. Matthias Preusser 🗣️ Talking about #TUXEDO3trial, presented at @ascocancer.bsky.social and published in Nature Medicine. 👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...

#MEDSIRatASCO Major milestone at #ASCO25! We presented the #TUXEDO3trial led by Dr. Matthias Preusser with Universität Wien as an oral presentation. The Phase II trial tested HER3-DXd in patients with brain mets & leptomeningeal disease.

Bring Your Research Ideas to Life — Meet with MEDSIR @wearemedsir at #ASCO25 to Get Started! 👉 buff.ly/BHKdQ7I MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas

#MEDSIRatASCO Our BD Manager, Aurelio del Pino, shares how we're expanding at #ASCO25, connecting with key players & forging new partnerships to drive clinical research. 💬 Hit play & join us: medsir.org/events/asco2... #MEDSIRLive #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO Educational sessions are underway and our team is already in Chicago! Want to meet with us at #ASCO25? Schedule your meeting here 👉 medsir.org/events/asco2... #MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#GoodMorning MEDSIR! Big day ahead with the oral presentation of our study #TUXEDO3trial 🕒 4:21–4:33 PM CDT 👨‍⚕️ Dr. Matthias Preusser 📍 S100bc | CNS Tumors Session Let’s connect in Chicago: medsir.org/events/asco2... #MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation

#MEDSIRatASCO @ascocancer.bsky.social 2025 kicks off today! We'll be sharing updates on #MEDSIR's participation in the most important oncology congress of the year. Stay tuned! 👀 #MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation

#MEDSIRatASCO is almost here! Our Scientific Impact Manager, Jose Rodríguez Morató, has a quick message for you. Let’s connect in Chicago and talk science! More on our #ASCO25 plans 👉🏼 www.medsir.org/events/asco2... #ASCO25 #MedicalResearch #CancerCare #Innovation

We are proud to share our latest work, now published in #Cancers 🧬 In this study, we investigated a novel combination of niraparib and aromatase inhibitors for patients with HR+/HER2- advanced breast cancer and germline BRCA mutations, a population with limited treatment options.

We're excited to share that the #MEDSIR team will be at the @ascocancer.bsky.social with an oral presentation and two posters. We would like to highlight our studies:

Delighted to host @medsir.bsky.social today at #BeaumontRCSICancerCentre, exploring novel ways to develop & expand investigator initiated trials for cancer in Ireland 🇮🇪, through @cancertrialsie.bsky.social & beyond Welcome @medsir.bsky.social @rcsi.bsky.social #LCSM